Brief: MAIA Biotechnology Announces Strong Efficacy Of THIO As Third-Line Treatment For Non-Small Cell Lung Cancer Patients
06/03/2024 13:51
March 6 (Reuters) - Maia Biotechnology Inc MAIA.A :
* MAIA BIOTECHNOLOGY ANNOUNCES STRONG EFFICACY OF THIO AS
THIRD-LINE TREATMENT FOR NON-SMALL CELL LUNG CANCER PATIENTS
* MAIA BIOTECHNOLOGY: COMBINATION THIO 180MG + CEMIPLIMAB
ACHIEVED
38% ORR IN DIFFICULT-TO-TREAT, THIRD-LINE NON-SMALL CELL LUNG
CANCER
* MAIA BIOTECHNOLOGY INC: SAFETY REMAINED CONSISTENT WITH
PREVIOUS
REPORTS
Source text for Eikon: ID:nBw9Cyvd9a
Further company coverage: MAIA.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Maia Biotechnology
See all newsBrief: Maia Biotechnology Says Ateganosine Plus Cemiplimab Outperforms Standard Chemotherapy Dcr In 3l Nsclc
Brief: Maia Biotechnology - To Terminate At The Market Offering Agreement Effective May 23, 2026 - SEC Filing
Brief: Maia Biotechnology Reports Overall Survival Exceeding Two Years For Eight Patients In Ongoing Phase 2 Clinical Trial In Non-Small Cell Lung Cancer
Brief: Maia Biotechnology Inc Enters Underwriting Agreement With Konik Capital Partners - SEC Filing
MAIA Biotechnology plunges after $30 million share sale